Zylox-Tonbridge Medical Technology Co., Ltd. commences an Equity Buyback Plan for 32,461,974 shares, representing 10% of its issued share capital, under the authorization approved on June 6, 2023.

Zylox-Tonbridge Medical Technology Co., Ltd. (SEHK:2190) commences share repurchases on November 7, 2023, under the program mandated by the shareholders in the Annual General Meeting held on June 6, 2023. As per the mandate, the company is authorized to repurchase up to 32,461,974 shares, representing 10% of its issued share capital. The purpose of repurchase program is to enhance the net assets and/or its earnings per share.

The repurchases will be made out of the funds legally available for such purpose and in accordance with the Articles of Association, the Listing Rules and the applicable PRC laws and regulations. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of June 6, 2023, the company had 332,401,001 shares in issue, consisting of 7,781,257 Domestic shares and 324,619,744 H shares.